Comparison of long-term clinical outcome after sirolimus-eluting stent implantation in patients with and without hemodialysis

International Heart Journal

Volumn 48, Issue 6, 2007, Pages 689-700

  Sasao, Hisataka ^a   Hotta, Daisuke ^a   Maeda, Takuto ^a   Saito, Norie ^a   Takagi, Satoru ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical outcome; Hemodialysis; Sirolimus eluting stents

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; HEPARIN; RAPAMYCIN; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RENAL DIALYSIS; SIROLIMUS; TREATMENT OUTCOME;

EID: 37649014331     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.689     Document Type: Article

References (21)

1. Samak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
2. Azar RR, Prpic R, Ho KK, et al. Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. Am J Cardiol 2000; 86: 485-9.
3. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-9.
4. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
5. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Mod 2003; 349: 1315-23.
6. Fajadet J, Morice MC, Bode C, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents. three-year results of the RAVEL trial. Circulation 2005; 111: 1040-4.
7. Zhang F, Ge J, Qian J, et al. Sirolimus-eluting stents in real-world patients with ST-scgment elevation acute myocardial infarction. Int Heart J 2007; 48: 303-11.
8. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty) Circulation 1988; 78: 486-502.
9. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82: 1193-202.
10. Tsuchihashi K, Hikita N, Hase M, et al. Role of hyperinsulinemia in atherosclerotic coronary arterial disease: studies of semi-quantitative coronary angiography. Intern Med 1999; 38: 691-7.
11. Hase H, Nakamura M, Joki N, et al. Independent predictors of restenosis after percutancous coronary revascularization in haemodialysis patients. Nephrol Dial Transplant 2001; 16: 2372-7.
12. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world". the Rapamycin-Eluting Stent Evaluaied At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109: 190-5.
13. Nakazawa G, Tanabe K, Aoki J, et al. Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-elutmg stents. Catheter Cardiovasc Interv 2007; 69: 808-14.
14. Suzuki K, Inoue N, Matsuo A, et al. Limitation on efficacy of sirolimus-eluting stent implantation in patients on hemodialysis. J Cardiol 2007; 49: 331-6. (Japanese)
15. Halkin A, Selzer F, Marroquin O, Laskey W, Detre K, Cohen H. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. J Invasive Cardiol 2006; 18: 577-83.
16. Yasuda & Kasuga H, Aoyama T, et al. Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol 2006; 17: 2322-32.
17. Le Feuvre C, Borentain M, Beygui F, Helft G, Batisse JP, Metzger JP. Comparison of short- and long-term out-comes of coronary angioplasty in patients with and without diabetes mellitas and with and without hemodialysis. Am J Cardiol 2003; 92: 721-5.
18. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218-23.
19. Neumann FJ, Desmet W, Grube E, et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005; 111: 2107-11.
20. Dibra A, Kastrati A, Alfonso F, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49: 616-23.
21. Sakamoto H, Ishikawa T, Mutoh M, et al. Effectiveness of a sirolimus-eluting stent (Cypher) for diffuse in-stent restenosis inside a bare metal stent. Int Heart J 2006; 47: 651-61.